- Company named as one of five young companies making an impact on the world to watch in 2019
- Enormous potential of company’s technology and role in early diagnosis of dementia highlighted
VANCOUVER, Jan. 9, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced that it has been named as one of five young companies making an impact on the world to watch in 2019 on Forbes.com.
The article highlights the huge cost of treating dementia, the substantial cost-of-care savings generated by early detection and Cognetivity’s use of artificial intelligence (AI) driven technology to improve diagnosis rates. The article can be read online at https://www.forbes.com/sites/alisoncoleman/2018/12/30/five-young-companies-making-an-impact-on-the-world-to-watch-in-2019
Cognetivity’s CEO and Director, Dr. Sina Habibi, commented: “2019 has got off to a great start, with Cognetivity being featured in Forbes as one of five young companies making an impact on the world to watch In 2019. Our main goal is, and always has been for our technology to help as many people as possible, and this recognition is another fantastic endorsement of our aims and the company’s enormous potential.”
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.
For more information please visit – www.cognetivity.com
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release
SOURCE Cognetivity Neurosciences Ltd
For further information: Email: firstname.lastname@example.org; For media enquiries contact: Josh Stanbury, Email: email@example.com